Swedish pharmaceutical company Moberg Pharma has completed enrolling patients in the ongoing Phase II trial of MOB-015 for the treatment of nail fungus (onychomycosis).
phase 2
Comments Off on Swedish pharmaceutical company Moberg Pharma has completed enrolling patients in the ongoing Phase II trial of MOB-015 for the treatment of nail fungus (onychomycosis).
May 282013